Shattuck Labs (STTK) Price & Analysis

Compare

232 Followers

STTK Stock Chart & Stats

$2.48

>-$0.01(-0.39%)

At close: Jan 08 4:00 PM EST

$2.48

>-$0.01(-0.39%)

Day’s Range― - ―

52-Week Range$0.69 - $2.71

Previous CloseN/A

Volume43.14K

Average Volume (3M)550.09K

Market Cap

$121.88M

Enterprise Value-$7.11M

Total Cash (Recent Filing)$42.55M

Total Debt (Recent Filing)$1.76M

Price to Earnings (P/E)―

Beta3.13

Next Earnings

Mar 17, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding63,151,790

10 Day Avg. Volume553,172

30 Day Avg. Volume550,087

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.77

Price to Sales (P/S)10.74

P/FCF Ratio-1.01

Enterprise Value/Market Cap-0.06

Enterprise Value/Revenue-7.11

Enterprise Value/Gross Profit8.22

Enterprise Value/Ebitda0.13

Forecast

1Y Price Target

$4.00

Price Target Upside61.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationsShattuck Labs is upgrading to a Buy recommendation with a $6 price target, indicating a bullish outlook on the SL-325 program.

Financial PerformanceShattuck announced 3Q25 results, posting EPS of ($0.14), compared with our estimate of ($0.22) and consensus of ($0.15).

Market PotentialSL-325 has the potential to enter and take up significant market share by addressing the immunogenicity concern with its DR3 targeting approach.

Bears Say

Therapy LimitationsA common emerging limitation among therapies in development is the durability of response and immunogenicity/anti-drug antibodies.

Shattuck Labs News

Shattuck Labs upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Shattuck Labs (STTK) to Buy from Neutral with a $6 price target The firm cites...

3d ago

STTK

Shattuck Labs reports Q3 EPS (14c), consensus (15c)

“In the third quarter of 2025, SL-325 became the first DR3 blocking antibody to enter clinical development, and...

28d ago

STTK

Shattuck Labs: Hold Rating Amidst Key Milestones and Strong Financial Position

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating today....

27d ago

STTK

Shattuck Labs Reports Improved Financial Performance

Shattuck Labs, Inc. ( ($STTK) ) has released its Q3 earnings. Here is a breakdown of the information...

28d ago

STTK

Shattuck Labs’ SL-325 Phase 1 Trial: A Key Development in Biopharmaceuticals

Shattuck Labs, Inc. (($STTK)) announced an update on their ongoing clinical study. Shattuck Labs, Inc. is conducting a...

1M ago

STTK

Shattuck Labs files to sell 105.27M shares of common stock for holders

16:07 EDT Shattuck Labs (STTK) files to sell 105.27M shares of common stock for holders Published first on...

3M ago

STTK

Shattuck Labs initiated with an Outperform at Wedbush

Wedbush initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $4 price target Published first on...

3M ago

STTK

Shattuck Labs Closes $103M Private Placement Deal

Shattuck Labs ( ($STTK) ) has issued an update. On August 26, 2025, Shattuck Labs announced the closing...

3M ago

STTK

Cautious Hold on Shattuck Labs Amid Early-Stage Developments and Strategic Positioning

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating on...

3M ago

STTK

Shattuck Labs Reports Q2 2025 Financial Results

Shattuck Labs, Inc. ( ($STTK) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

STTK

Shattuck Labs says IND for SL-325 for treatment of IBD in effect

Shattuck Labs (STTK) announced that the Company’s Investigational New Drug application submitted to the U.S. Food and Drug...

4M ago

STTK

Promising Financial Position and SL-325 Potential Drive Buy Rating for Shattuck Labs

TD Cowen analyst Marc Frahm has maintained their bullish stance on STTK stock, giving a Buy rating today....

4M ago

STTK

Shattuck Labs price target lowered to $2 from $4 at Leerink

Leerink analyst Faisal Khurshid lowered the firm’s price target on Shattuck Labs (STTK) to $2 from $4 and...

4M ago

STTK

Cautious Optimism for Shattuck Labs: Hold Rating Amid Promising Financials and Early Clinical Development

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating today....

4M ago

STTK

STTK FAQ

What was Shattuck Labs’s price range in the past 12 months?

Shattuck Labs lowest stock price was $0.69 and its highest was $2.71 in the past 12 months.

What is Shattuck Labs’s market cap?

Shattuck Labs’s market cap is $121.88M.

When is Shattuck Labs’s upcoming earnings report date?

Shattuck Labs’s upcoming earnings report date is Mar 17, 2026 which is in 103 days.

How were Shattuck Labs’s earnings last quarter?

Shattuck Labs released its earnings results on Nov 06, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.149 by $0.009.

Is Shattuck Labs overvalued?

According to Wall Street analysts Shattuck Labs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shattuck Labs pay dividends?

Shattuck Labs does not currently pay dividends.

What is Shattuck Labs’s EPS estimate?

Shattuck Labs’s EPS estimate is -0.14.

How many shares outstanding does Shattuck Labs have?

Shattuck Labs has 63,151,790 shares outstanding.

What happened to Shattuck Labs’s price movement after its last earnings report?

Shattuck Labs reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.149. Following the earnings report the stock price went up 1.02%.

Which hedge fund is a major shareholder of Shattuck Labs?

Currently, no hedge funds are holding shares in STTK

Shattuck Labs Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.84%

Trailing 12-Months

Asset Growth

-49.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs (STTK) Earnings & Revenues

Historic Earnings Reports

STTK Stock 12 Month Forecast

Average Price Target

$4.00

▲(61.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.41,2.686153846153846,2.9623076923076925,3.2384615384615385,3.514615384615385,3.790769230769231,4.066923076923077,4.343076923076923,4.61923076923077,4.895384615384615,5.171538461538462,5.447692307692307,5.723846153846154,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.41,2.5323076923076924,2.6546153846153846,2.776923076923077,2.8992307692307695,3.0215384615384617,3.143846153846154,3.266153846153846,3.3884615384615384,3.510769230769231,3.6330769230769233,3.7553846153846155,3.8776923076923078,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.41,2.3784615384615386,2.346923076923077,2.3153846153846156,2.283846153846154,2.2523076923076926,2.220769230769231,2.189230769230769,2.1576923076923076,2.126153846153846,2.0946153846153845,2.063076923076923,2.0315384615384615,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.09,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >